



# NOMISMA HEALTHCARE

*Polymers for Advance drug delivery*

## About us

### The Company

Nomisma Healthcare is a comprehensive, integrated manufacturing firm and consultancy, based in Nomisma Healthcare. Our top management consists of highly experienced and qualified polymer scientist having years of specialized synthesis experience in different sectors.

Founded in the year 2016, our company has provided Bio-Polymers to a growing list of highly satisfied company, a majority of whom are market leaders in formulations developments. Our success as a business partner was recognized in -- **identify special achievement or recognition.**

We take special pride in our skills of providing viable and successful marketing strategies and analysis to clients. In addition, our handling of promotional activities at special events and exhibitions are well known for efficiency and efficacy.

PRODUCT ID	NAME	PRICE (USD)/Kg	Ratio and End group
PLLA	Poly-L Lactic Acid	1000	100:00 , -COOH
PDLA	Poly-D Lactic acid	1715	00:100, -COOH
PDLLA	Poly DL lactic Acid	1715	50:50,70:30,30:70, -COOH
PLLA-Ester	Poly-L Lactide Ester	2140	100:00, Ethyl and lauryl Ester
PDLA-Ester	Poly-D Lactide Ester	2150	00:100 Ethyl and lauryl Ester
PDLLA-Ester	Poly-DL Lactide Ester	2150	50:50,70:30,30:70,Ethyl and lauryl Ester
PLLGA	Poly-L-lactic acid co glycolic acid	2150-2575	75:25,50:50,85:25,55:45,-COOH
PDLLGA	Poly-DL-lactic acid co glycolic acid	2150-2575	75:25,50:50,85:25,55:45,-COOH
PDLGA	Poly-D-lactic acid co glycolic acid	2150-2575	75:25,50:50,85:25,55:45,-COOH
PGA	Poly Glycolic Acid	1290	-COOH
*****Viscosity range is 0.2-2.5 dL/g (Molecular weight 15 kD to 250 kD)			

**Table 1. PLA/PLGA-based drug products that are available in the U.S.**

Drug Product	Active Ingredient	Dosage Form, Route of Administration	Strength,	Approval Date(s), Indication(s)	Characteristics of PLA/PLGA (described in product labeling)
Vivitrol	Naltrexone	Microsphere, Intramuscular	380 mg every 4-weeks	1984, Indicated for the treatment of alcohol dependence	PLGA, L/G: 75/25
Zoladex	Goserelin acetate	Implant, Subcutaneous	3.6 mg or 10.8 mg every 28 days	1989 (3.6 mg), 1996 (10.8 mg), Indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 carcinoma of the prostate	PLGA (13.3-14.3 mg/dose) No characterization information
Lupron Depot	Leuprolide acetate	Microsphere, Intramuscular	7.5 mg, every month 22.5 mg, every 3-months 30 mg, every 4-months 45 mg, every 6-months	1989, Indicated for palliative treatment of advanced prostatic cancer	7.5 mg: PLGA (66.2 mg/dose) 22.5 mg: PLA (198.6 mg/dose) 30 mg: PLA (264.8 mg/dose) 45 mg: PLA (169.9 mg/dose) No characterization information
Lupron Depot-PED	Leuprolide acetate	Microsphere, Intramuscular	7.5 mg, 11.25 mg, or 15 mg every month 11.25 mg or 30 mg every 3-months	1993, Indicated for the treatment of children with central precocious puberty (CPP)	7.5 mg, 11.25 mg, and 15 mg: PLGA (66.2/99.3/132.4 mg/dose) 11.25 mg and 30 mg: PLA (99.3/264.8 mg/dose) No characterization information
Lupron	Leuprolide acetate	Microsphere, Intramuscular	3.75 mg, every month	1995, Indicated for management of endometriosis	PLGA (33.1 mg/dose) No characterization information
Sandostatin LAR	Octreotide	Microsphere, Subcutaneous	10 mg, 20 mg, or 30 mg every 4-weeks	1998, Indicated for acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, profuse watery diarrhea associated with VIP-secreting tumors	10 mg, 20 mg, and 30 mg: glucose star polymer, PLGA (188.8/377.6/566.4 mg/dose)
Atridox	Doxycycline hyclate	In situ forming gel Periodontal	50 mg	1998, Indicated for the treatment of chronic adult periodontitis for a gain in clinical attachment, reduction in probing depth, and reduction in bleeding on probing	PLA (36.7%/dose) No characterization data
Trelstar	Triptorelin pamoate	Microsphere, Intramuscular	3.75 mg every 4-weeks 11.25 mg every 12-weeks 22.5 mg every 24-weeks	2000 (3.75 mg), 2001 (11.25 mg), 2010 (22.5 mg), Indicated for the palliative treatment of advanced prostate cancer	3.75 mg, 11.25 mg, and 22.5 mg: PLGA (136/118/182 mg/dose) No characterization information
Arestin	Minocycline HCl	Microsphere, Periodontal	1 mg, variable dosing frequency	2001, Indicated as an adjunct to scaling and root planning procedures in patients with adult periodontitis	PLGA No characterization information
Eligard	Leuprolide acetate	In situ forming gel, Subcutaneous	7.5 mg every month 22.5 mg every 3-months 30 mg every 4-months 45 mg every 6-months	2002 (7.5 mg and 22.5 mg), 2003 (30 mg), and 2004 (45 mg), Indicated for the palliative treatment of advanced prostate cancer	7.5 mg: PLGA (82.5 mg/dose), carboxyl endgroups, L/G: 50/50 22.5 mg and 30 mg: PLGA (158.6/211.5 mg/dose), copolymer with hexanediol, L/G: 75/25 45 mg: PLGA (165 mg/dose), copolymer with hexanediol, L/G: 85/15
Risperdal Consta	Risperidone	Microsphere, Intramuscular	12.5 mg, 25 mg, 37.5 mg, or 50 mg every 2-weeks	2003, Indicated for the treatment of schizophrenia and bipolar I disorder	12.5 mg, 25 mg, 37.5 mg, and 50 mg: PLGA, L/G: 72/25
Ozurdex	Dexamethasone	Microsphere, Subcutaneous	0.7 mg, variable dosing frequency	2009, Indicated for the treatment of macular edema, non-infectious uveitis, and diabetic macular edema	PLGA No characterization information
Bydureon	Exenatide	Microsphere; Tablet	2 mg, every 7-days	2012, Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes	PLGA (37.2 mg/dose), L/G: 50/50
Lupaneta Pack	Leuprolide acetate; Norethindrone acetate	Intramuscular; Oral	3.75 mg every month; 5 mg daily	2012, Indicated for initial management of the painful symptoms of endometriosis and management of recurrence of symptoms	DL-lactic and glycolic acids copolymer (33.1 mg), no characterization data
Signifor LAR	Pasireotide pamoate	Microsphere, Intramuscular	20 mg, 40 mg, or 60 mg every 28-days	2014, Indicated for the treatment of patients with acromegaly	20 mg, 40 mg, and 60 mg: a mixture of two PLGAs per dose PLGA I (26.29/52.58/78.87 mg/dose), L/G: 50-60/40-50 PLGA II (26.29/52.58/78.87 mg/dose), L/G: 50/50

A preferred contract manufacturing organization for Advance bio-polymers used in drug delivery system



Our Assets

Our Clients

Kwality Pharmaceuticals limited

Solvay

Atco Pharma for Pharmaceutical Industries

### **Contact Information**

Visit [www.nomismahealthcare.in](http://www.nomismahealthcare.in)

Call 8200708063

Write to Gorwa BIDC,Vadodara,Gujarat,India

Email us : [info.nomisma@gmail.com](mailto:info.nomisma@gmail.com)

[neha@nomismahealthcare.in](mailto:neha@nomismahealthcare.in)

---